APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD133 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CD133 Antibody Market Analysis and Forecast 2026-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchCD133 Antibody Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal CD133 Antibody Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CD133 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD133 Antibody Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal CD133 Antibody Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global CD133 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CD133 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CD133 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CD133 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CD133 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CD133 Antibody include Thermo Fisher Scientific, Boster Biological Technology, United States Biological, Proteintech, NSJ Bioreagents, Miltenyi Biotec, HUABIO, GeneTex and Cell Signaling Technology, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CD133 Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CD133 Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for CD133 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CD133 Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CD133 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CD133 Antibody revenue, projected growth trends, production technology, application and end-user industry.

CD133 Antibody Segment by Company

Thermo Fisher Scientific

Boster Biological Technology

United States Biological

Proteintech

NSJ Bioreagents

Miltenyi Biotec

HUABIO

GeneTex

Cell Signaling Technology

Bioss

BioLegend

Beckman Coulter

Abcam

CD133 Antibody Segment by Type

Polyclonal

Monoclonal

CD133 Antibody Segment by Application

Western Blot

Enzyme Linked Immunosorbent Assay

Immunocytochemistry

Immunohistochemistry

Others

CD133 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD133 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD133 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD133 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CD133 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CD133 Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD133 Antibody revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CD133 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polyclonal Major Player Table 3. Monoclonal Major Player Table 4. Global CD133 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Western Blot Major Player Table 6. Enzyme Linked Immunosorbent Assay Major Player Table 7. Immunocytochemistry Major Player Table 8. Immunohistochemistry Major Player Table 9. Others Major Player Table 10. CD133 Antibody Industry Trends Table 11. CD133 Antibody Industry Drivers Table 12. CD133 Antibody Industry Opportunities and Challenges Table 13. CD133 Antibody Industry Restraints Table 14. Global CD133 Antibody Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global CD133 Antibody Market Size by Region (2021-2026) & (US$ Million) Table 16. Global CD133 Antibody Market Share by Region (2021-2026) Table 17. Global CD133 Antibody Market Size by Region (2027-2032) & (US$ Million) Table 18. Global CD133 Antibody Market Share by Region (2027-2032) Table 19. Global CD133 Antibody Revenue by Players (US$ Million) & (2021-2026) Table 20. Global CD133 Antibody Revenue Market Share by Players (2021-2026) Table 21. Global CD133 Antibody Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global CD133 Antibody Key Players Headquarters & Area Served Table 23. Global CD133 Antibody Players, Product Type & Application Table 24. Global CD133 Antibody Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global CD133 Antibody by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global CD133 Antibody Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global CD133 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 29. Global CD133 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 30. Global CD133 Antibody Revenue Market Share by Type (2021-2026) Table 31. Global CD133 Antibody Revenue Market Share by Type (2027-2032) Table 32. Global CD133 Antibody Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global CD133 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 34. Global CD133 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 35. Global CD133 Antibody Revenue Market Share by Application (2021-2026) Table 36. Global CD133 Antibody Revenue Market Share by Application (2027-2032) Table 37. Thermo Fisher Scientific Company Information Table 38. Thermo Fisher Scientific Business Overview Table 39. Thermo Fisher Scientific CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Thermo Fisher Scientific CD133 Antibody Product Portfolio Table 41. Thermo Fisher Scientific Recent Development Table 42. Boster Biological Technology Company Information Table 43. Boster Biological Technology Business Overview Table 44. Boster Biological Technology CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Boster Biological Technology CD133 Antibody Product Portfolio Table 46. Boster Biological Technology Recent Development Table 47. United States Biological Company Information Table 48. United States Biological Business Overview Table 49. United States Biological CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. United States Biological CD133 Antibody Product Portfolio Table 51. United States Biological Recent Development Table 52. Proteintech Company Information Table 53. Proteintech Business Overview Table 54. Proteintech CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Proteintech CD133 Antibody Product Portfolio Table 56. Proteintech Recent Development Table 57. NSJ Bioreagents Company Information Table 58. NSJ Bioreagents Business Overview Table 59. NSJ Bioreagents CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. NSJ Bioreagents CD133 Antibody Product Portfolio Table 61. NSJ Bioreagents Recent Development Table 62. Miltenyi Biotec Company Information Table 63. Miltenyi Biotec Business Overview Table 64. Miltenyi Biotec CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Miltenyi Biotec CD133 Antibody Product Portfolio Table 66. Miltenyi Biotec Recent Development Table 67. HUABIO Company Information Table 68. HUABIO Business Overview Table 69. HUABIO CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. HUABIO CD133 Antibody Product Portfolio Table 71. HUABIO Recent Development Table 72. GeneTex Company Information Table 73. GeneTex Business Overview Table 74. GeneTex CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. GeneTex CD133 Antibody Product Portfolio Table 76. GeneTex Recent Development Table 77. Cell Signaling Technology Company Information Table 78. Cell Signaling Technology Business Overview Table 79. Cell Signaling Technology CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Cell Signaling Technology CD133 Antibody Product Portfolio Table 81. Cell Signaling Technology Recent Development Table 82. Bioss Company Information Table 83. Bioss Business Overview Table 84. Bioss CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Bioss CD133 Antibody Product Portfolio Table 86. Bioss Recent Development Table 87. BioLegend Company Information Table 88. BioLegend Business Overview Table 89. BioLegend CD133 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. BioLegend CD133 Antibody Product Portfolio Table 91. BioLegend Recent Development Table 92. Beckman Coulter Company Information Table 93. Beckman Coulter Business Overview Table 94. Beckman Coulter CD133 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Beckman Coulter CD133 Antibody Product Portfolio Table 96. Beckman Coulter Recent Development Table 97. Abcam Company Information Table 98. Abcam Business Overview Table 99. Abcam CD133 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Abcam CD133 Antibody Product Portfolio Table 101. Abcam Recent Development Table 102. North America CD133 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 103. North America CD133 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 104. North America CD133 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 105. North America CD133 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 106. North America CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America CD133 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 108. North America CD133 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe CD133 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe CD133 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe CD133 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe CD133 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe CD133 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe CD133 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 116. China CD133 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 117. China CD133 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 118. China CD133 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 119. China CD133 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia CD133 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia CD133 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia CD133 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia CD133 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia CD133 Antibody Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia CD133 Antibody Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia CD133 Antibody Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA CD133 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA CD133 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA CD133 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA CD133 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA CD133 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA CD133 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. CD133 Antibody Image Figure 2. Global CD133 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD133 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polyclonal Image Figure 5. Monoclonal Image Figure 6. Global CD133 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CD133 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 8. Western Blot Image Figure 9. Enzyme Linked Immunosorbent Assay Image Figure 10. Immunocytochemistry Image Figure 11. Immunohistochemistry Image Figure 12. Others Image Figure 13. Global CD133 Antibody Market Size (US$ Million) & (2021-2032) Figure 14. Global CD133 Antibody Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global CD133 Antibody Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global CD133 Antibody Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global CD133 Antibody Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global CD133 Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global CD133 Antibody Revenue Market Share by Type (2021-2032) Figure 21. Global CD133 Antibody Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global CD133 Antibody Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global CD133 Antibody Revenue Market Share by Application (2021-2032) Figure 24. North America CD133 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America CD133 Antibody Revenue Share by Type (2021-2032) Figure 26. North America CD133 Antibody Revenue Share by Application (2021-2032) Figure 27. North America CD133 Antibody Revenue Share by Country (2021-2032) Figure 28. United States CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe CD133 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe CD133 Antibody Revenue Share by Type (2021-2032) Figure 33. Europe CD133 Antibody Revenue Share by Application (2021-2032) Figure 34. Europe CD133 Antibody Revenue Share by Country (2021-2032) Figure 35. Germany CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China CD133 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China CD133 Antibody Revenue Share by Type (2021-2032) Figure 45. China CD133 Antibody Revenue Share by Application (2021-2032) Figure 46. Asia CD133 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia CD133 Antibody Revenue Share by Type (2021-2032) Figure 48. Asia CD133 Antibody Revenue Share by Application (2021-2032) Figure 49. Asia CD133 Antibody Revenue Share by Region (2021-2032) Figure 50. Japan CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA CD133 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA CD133 Antibody Revenue Share by Type (2021-2032) Figure 58. SAMEA CD133 Antibody Revenue Share by Application (2021-2032) Figure 59. SAMEA CD133 Antibody Revenue Share by Country (2021-2032) Figure 60. Brazil CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt CD133 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Enzyme Linked Immunosorbent Assay
  • Immunocytochemistry
  • Immunohistochemistry
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Boster Biological Technology
  • United States Biological
  • Proteintech
  • NSJ Bioreagents
  • Miltenyi Biotec
  • HUABIO
  • GeneTex
  • Cell Signaling Technology
  • Bioss
  • BioLegend
  • Beckman Coulter
  • Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CD133 Antibody Market by Type
  3. 1.2.1 Global CD133 Antibody Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polyclonal
  5. 1.2.3 Monoclonal
  6. 1.3 CD133 Antibody Market by Application
  7. 1.3.1 Global CD133 Antibody Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Western Blot
  9. 1.3.3 Enzyme Linked Immunosorbent Assay
  10. 1.3.4 Immunocytochemistry
  11. 1.3.5 Immunohistochemistry
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 CD133 Antibody Market Dynamics
  1. 2.1 CD133 Antibody Industry Trends
  2. 2.2 CD133 Antibody Industry Drivers
  3. 2.3 CD133 Antibody Industry Opportunities and Challenges
  4. 2.4 CD133 Antibody Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CD133 Antibody Market Perspective (2021-2032)
  2. 3.2 Global CD133 Antibody Growth Trends by Region
  3. 3.2.1 Global CD133 Antibody Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CD133 Antibody Market Size by Region (2021-2026)
  5. 3.2.3 Global CD133 Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CD133 Antibody Revenue by Players
  2. 4.1.1 Global CD133 Antibody Revenue by Players (2021-2026)
  3. 4.1.2 Global CD133 Antibody Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CD133 Antibody Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CD133 Antibody Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CD133 Antibody Key Players Headquarters & Area Served
  7. 4.4 Global CD133 Antibody Players, Product Type & Application
  8. 4.5 Global CD133 Antibody Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CD133 Antibody Market CR5 and HHI
  11. 4.6.3 2025 CD133 Antibody Tier 1, Tier 2, and Tier 3
5 CD133 Antibody Market Size by Type
  1. 5.1 Global CD133 Antibody Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CD133 Antibody Revenue by Type (2021-2032)
  3. 5.3 Global CD133 Antibody Revenue Market Share by Type (2021-2032)
6 CD133 Antibody Market Size by Application
  1. 6.1 Global CD133 Antibody Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CD133 Antibody Revenue by Application (2021-2032)
  3. 6.3 Global CD133 Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific CD133 Antibody Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific CD133 Antibody Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Boster Biological Technology
  8. 7.2.1 Boster Biological Technology Company Information
  9. 7.2.2 Boster Biological Technology Business Overview
  10. 7.2.3 Boster Biological Technology CD133 Antibody Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Boster Biological Technology CD133 Antibody Product Portfolio
  12. 7.2.5 Boster Biological Technology Recent Developments
  13. 7.3 United States Biological
  14. 7.3.1 United States Biological Company Information
  15. 7.3.2 United States Biological Business Overview
  16. 7.3.3 United States Biological CD133 Antibody Revenue and Gross Margin (2021-2026)
  17. 7.3.4 United States Biological CD133 Antibody Product Portfolio
  18. 7.3.5 United States Biological Recent Developments
  19. 7.4 Proteintech
  20. 7.4.1 Proteintech Company Information
  21. 7.4.2 Proteintech Business Overview
  22. 7.4.3 Proteintech CD133 Antibody Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Proteintech CD133 Antibody Product Portfolio
  24. 7.4.5 Proteintech Recent Developments
  25. 7.5 NSJ Bioreagents
  26. 7.5.1 NSJ Bioreagents Company Information
  27. 7.5.2 NSJ Bioreagents Business Overview
  28. 7.5.3 NSJ Bioreagents CD133 Antibody Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NSJ Bioreagents CD133 Antibody Product Portfolio
  30. 7.5.5 NSJ Bioreagents Recent Developments
  31. 7.6 Miltenyi Biotec
  32. 7.6.1 Miltenyi Biotec Company Information
  33. 7.6.2 Miltenyi Biotec Business Overview
  34. 7.6.3 Miltenyi Biotec CD133 Antibody Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Miltenyi Biotec CD133 Antibody Product Portfolio
  36. 7.6.5 Miltenyi Biotec Recent Developments
  37. 7.7 HUABIO
  38. 7.7.1 HUABIO Company Information
  39. 7.7.2 HUABIO Business Overview
  40. 7.7.3 HUABIO CD133 Antibody Revenue and Gross Margin (2021-2026)
  41. 7.7.4 HUABIO CD133 Antibody Product Portfolio
  42. 7.7.5 HUABIO Recent Developments
  43. 7.8 GeneTex
  44. 7.8.1 GeneTex Company Information
  45. 7.8.2 GeneTex Business Overview
  46. 7.8.3 GeneTex CD133 Antibody Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GeneTex CD133 Antibody Product Portfolio
  48. 7.8.5 GeneTex Recent Developments
  49. 7.9 Cell Signaling Technology
  50. 7.9.1 Cell Signaling Technology Company Information
  51. 7.9.2 Cell Signaling Technology Business Overview
  52. 7.9.3 Cell Signaling Technology CD133 Antibody Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Cell Signaling Technology CD133 Antibody Product Portfolio
  54. 7.9.5 Cell Signaling Technology Recent Developments
  55. 7.10 Bioss
  56. 7.10.1 Bioss Company Information
  57. 7.10.2 Bioss Business Overview
  58. 7.10.3 Bioss CD133 Antibody Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bioss CD133 Antibody Product Portfolio
  60. 7.10.5 Bioss Recent Developments
  61. 7.11 BioLegend
  62. 7.11.1 BioLegend Company Information
  63. 7.11.2 BioLegend Business Overview
  64. 7.11.3 BioLegend CD133 Antibody Revenue and Gross Margin (2021-2026)
  65. 7.11.4 BioLegend CD133 Antibody Product Portfolio
  66. 7.11.5 BioLegend Recent Developments
  67. 7.12 Beckman Coulter
  68. 7.12.1 Beckman Coulter Company Information
  69. 7.12.2 Beckman Coulter Business Overview
  70. 7.12.3 Beckman Coulter CD133 Antibody Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Beckman Coulter CD133 Antibody Product Portfolio
  72. 7.12.5 Beckman Coulter Recent Developments
  73. 7.13 Abcam
  74. 7.13.1 Abcam Company Information
  75. 7.13.2 Abcam Business Overview
  76. 7.13.3 Abcam CD133 Antibody Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Abcam CD133 Antibody Product Portfolio
  78. 7.13.5 Abcam Recent Developments
8 North America
  1. 8.1 North America CD133 Antibody Revenue (2021-2032)
  2. 8.2 North America CD133 Antibody Revenue by Type (2021-2032)
  3. 8.2.1 North America CD133 Antibody Revenue by Type (2021-2026)
  4. 8.2.2 North America CD133 Antibody Revenue by Type (2027-2032)
  5. 8.3 North America CD133 Antibody Revenue Share by Type (2021-2032)
  6. 8.4 North America CD133 Antibody Revenue by Application (2021-2032)
  7. 8.4.1 North America CD133 Antibody Revenue by Application (2021-2026)
  8. 8.4.2 North America CD133 Antibody Revenue by Application (2027-2032)
  9. 8.5 North America CD133 Antibody Revenue Share by Application (2021-2032)
  10. 8.6 North America CD133 Antibody Revenue by Country
  11. 8.6.1 North America CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CD133 Antibody Revenue by Country (2021-2026)
  13. 8.6.3 North America CD133 Antibody Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe CD133 Antibody Revenue (2021-2032)
  2. 9.2 Europe CD133 Antibody Revenue by Type (2021-2032)
  3. 9.2.1 Europe CD133 Antibody Revenue by Type (2021-2026)
  4. 9.2.2 Europe CD133 Antibody Revenue by Type (2027-2032)
  5. 9.3 Europe CD133 Antibody Revenue Share by Type (2021-2032)
  6. 9.4 Europe CD133 Antibody Revenue by Application (2021-2032)
  7. 9.4.1 Europe CD133 Antibody Revenue by Application (2021-2026)
  8. 9.4.2 Europe CD133 Antibody Revenue by Application (2027-2032)
  9. 9.5 Europe CD133 Antibody Revenue Share by Application (2021-2032)
  10. 9.6 Europe CD133 Antibody Revenue by Country
  11. 9.6.1 Europe CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CD133 Antibody Revenue by Country (2021-2026)
  13. 9.6.3 Europe CD133 Antibody Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China CD133 Antibody Revenue (2021-2032)
  2. 10.2 China CD133 Antibody Revenue by Type (2021-2032)
  3. 10.2.1 China CD133 Antibody Revenue by Type (2021-2026)
  4. 10.2.2 China CD133 Antibody Revenue by Type (2027-2032)
  5. 10.3 China CD133 Antibody Revenue Share by Type (2021-2032)
  6. 10.4 China CD133 Antibody Revenue by Application (2021-2032)
  7. 10.4.1 China CD133 Antibody Revenue by Application (2021-2026)
  8. 10.4.2 China CD133 Antibody Revenue by Application (2027-2032)
  9. 10.5 China CD133 Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CD133 Antibody Revenue (2021-2032)
  2. 11.2 Asia CD133 Antibody Revenue by Type (2021-2032)
  3. 11.2.1 Asia CD133 Antibody Revenue by Type (2021-2026)
  4. 11.2.2 Asia CD133 Antibody Revenue by Type (2027-2032)
  5. 11.3 Asia CD133 Antibody Revenue Share by Type (2021-2032)
  6. 11.4 Asia CD133 Antibody Revenue by Application (2021-2032)
  7. 11.4.1 Asia CD133 Antibody Revenue by Application (2021-2026)
  8. 11.4.2 Asia CD133 Antibody Revenue by Application (2027-2032)
  9. 11.5 Asia CD133 Antibody Revenue Share by Application (2021-2032)
  10. 11.6 Asia CD133 Antibody Revenue by Country
  11. 11.6.1 Asia CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CD133 Antibody Revenue by Country (2021-2026)
  13. 11.6.3 Asia CD133 Antibody Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CD133 Antibody Revenue (2021-2032)
  2. 12.2 SAMEA CD133 Antibody Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CD133 Antibody Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CD133 Antibody Revenue by Type (2027-2032)
  5. 12.3 SAMEA CD133 Antibody Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CD133 Antibody Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CD133 Antibody Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CD133 Antibody Revenue by Application (2027-2032)
  9. 12.5 SAMEA CD133 Antibody Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CD133 Antibody Revenue by Country
  11. 12.6.1 SAMEA CD133 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CD133 Antibody Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CD133 Antibody Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst